查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1782162

发炎性肠道疾病治疗市场机会、成长动力、产业趋势分析及 2025 - 2034 年预测

Inflammatory Bowel Disease Treatment Market Opportunity, Growth Drivers, Industry Trend Analysis, and Forecast 2025 - 2034
出版日期: | 出版商: Global Market Insights Inc. | 英文 145 Pages | 商品交期: 2-3个工作天内

价格
简介目录

2024年，全球发炎性肠道疾病治疗市场规模达239亿美元，预计到2034年将以6.5%的复合年增长率成长，达到445亿美元。这一增长主要源于全球发炎性肠道疾病（IBD）盛行率的上升，包括克隆氏症和溃疡性结肠炎，以及早期诊断和治疗管道的不断扩展。饮食习惯的改变、久坐的生活方式以及环境因素导致IBD病例数不断增加，尤其是在已开发国家。加强宣传活动和更优惠的报销结构正在提高诊断率和患者依从性。

发炎性肠道疾病治疗市场 - IMG1

针对生物製剂和小分子等治疗方法的创新显着提高了治疗效果，并减少了治疗相关併发症。政府以公共资金和更快的监管审查形式提供的支持也促进了下一代疗法的开发和应用。随着患者人数的稳定增长，对能够改善生活品质和减少疾病发作的长期有效解决方案的需求持续增长。这些因素共同塑造了未来十年IBD疗法强劲且充满活力的市场环境。

市场范围
起始年份 2024
预测年份 2025-2034
起始值 239亿美元
预测值 445亿美元
复合年增长率 6.5%

2024年，克隆氏症细分市场占据56.5%的市场份额，预计2025-2034年期间的复合年增长率为6.3%。这一增长主要归因于年轻群体中新诊断病例的增加，尤其是在北美和欧洲。由于克隆氏症可涉及胃肠道的任何部位并渗透至更深的组织层，因此与溃疡性结肠炎相比，它往往需要更复杂、更长期的治疗方法。因此，医疗保健提供者越来越多地使用免疫抑制剂和生物製剂等高价值疗法。包括Janus激酶抑制剂和抗整合素药物在内的先进治疗方案的日益普及，重新定义了该疾病的治疗方式，并显着促进了该细分市场的成长。

注射疗法领域在2024年创造了最高的收入，价值182亿美元，预计到2034年将维持6.4%的复合年增长率。这个领域主要由生物製剂（尤其是单株抗体）的广泛应用引领，这些生物製剂通常透过注射给药。这些疗法透过精准靶向发炎通路，已成为治疗中度至重度发炎性肠道疾病（IBD）的基石。在分子层面调节免疫活性的药物已被证明在维持缓解和最大程度降低疾病復发方面非常有效，尤其对于对传统药物无效的患者。长效注射剂也有助于提高依从性并提升患者满意度。

2024年，美国发炎性肠道疾病治疗市场规模达88亿美元。该市场的成长动力源自于不同人群中克隆氏症和溃疡性结肠炎发生率的上升。诊断能力的提升、专科医生就诊机会的增加以及标靶治疗的广泛应用，都在加速市场发展。长效皮下注射剂和缓释製剂等创新药物传递技术的出现，提高了患者的治疗顺从性。这些进步使患者更容易控制病情并维持长期缓解，进一步刺激了对先进疗法的需求。

全球发炎性肠道疾病治疗市场的主要参与者包括辉瑞、百健、武田、Dr Falk、强生、CELLTRION、艾伯维、辉凌、默克、优时比、诺华、Tillotts Pharma、礼来和安进。这些公司透过策略性投资和创新药物开发持续影响市场方向。为了巩固其在发炎性肠道疾病治疗领域的影响力，领先的製药公司正在推动多管齐下的策略，包括研究驱动的创新、监管参与和合作伙伴关係。

该公司正在大力投资临床试验，以开发疗效更高、副作用更少的新型生物製剂和小分子药物。透过授权交易、併购等方式拓展产品线也已成为常见策略。许多公司正与卫生部门密切合作，以加快审批速度并确保广泛的报销管道。

目录

第一章：方法论与范围

第二章：执行摘要

第三章：行业洞察

  • 产业生态系统分析
  • 产业衝击力
    • 成长动力
      • IBD盛行率不断上升
      • 技术进步
      • 优惠的报销政策
      • 对 IBD 症状的认识和早期诊断不断提高
    • 产业陷阱与挑战
      • 严格的监管情景
      • 治疗费用高昂
    • 市场机会
      • 生物製剂和标靶疗法的采用率不断上升
      • 新兴市场的扩张
  • 成长潜力分析
  • 报销场景
  • 监管格局
  • 管道分析
  • 投资情境展望
  • 治疗转换模式或排序趋势
  • 流行病学情景
  • 未来市场趋势/主要市场疗法
  • 品牌分析
  • 波特的分析
  • PESTEL分析

第四章：竞争格局

  • 介绍
  • 公司市占率分析
    • 全球的
    • 北美洲
    • 欧洲
    • 亚太地区
    • 拉丁美洲
    • MEA
  • 主要市场参与者的竞争分析
  • 公司矩阵分析
  • 竞争定位矩阵
  • 关键进展
    • 併购
    • 伙伴关係和合作
    • 新产品发布
    • 扩张计划

第五章：市场估计与预测：按治疗类型，2021 - 2034 年

  • 主要趋势
  • 克罗恩病
  • 溃疡性结肠炎

第六章：市场估计与预测：按药物类别，2021 - 2034 年

  • 主要趋势
  • 一线治疗
    • 氨基水杨酸盐
    • 皮质类固醇
  • 二线治疗
    • TNF抑制剂
    • 白血球介素抑制剂
    • JAK抑制剂
    • 抗整合素
  • 合併治疗
    • TNF抑制剂+硫嘌呤
    • 其他联合疗法

第七章：市场估计与预测：按管理路线，2021 - 2034 年

  • 主要趋势
  • 注射剂
  • 口服

第八章：市场估计与预测：按配销通路，2021 - 2034 年

  • 主要趋势
  • 传统实体店
  • 电子商务

第九章：市场估计与预测：按地区，2021 - 2034 年

  • 主要趋势
  • 北美洲
    • 我们
    • 加拿大
  • 欧洲
    • 德国
    • 英国
    • 法国
    • 西班牙
    • 义大利
    • 荷兰
  • 亚太地区
    • 中国
    • 日本
    • 印度
    • 澳洲
    • 韩国
  • 拉丁美洲
    • 巴西
    • 墨西哥
    • 阿根廷
  • 中东和非洲
    • 南非
    • 沙乌地阿拉伯
    • 阿联酋

第十章：公司简介

  • AbbVie
  • Amgen
  • Biogen
  • CELLTRION
  • Dr Falk
  • Ferring
  • Johnson & Johnson
  • Lilly
  • Merck
  • Novartis
  • Pfizer
  • Takeda
  • Tillotts Pharma
  • UCB
简介目录
Product Code: 10194

The Global Inflammatory Bowel Disease Treatment Market was valued at USD 23.9 billion in 2024 and is estimated to grow at a CAGR of 6.5% to reach USD 44.5 billion by 2034. This growth is primarily driven by a rising global prevalence of IBD, including Crohn's disease and ulcerative colitis, as well as expanding access to early diagnosis and treatment. Changing diets, sedentary lifestyles, and environmental factors are contributing to the increasing number of IBD cases, especially in developed nations. Enhanced awareness campaigns and more favorable reimbursement structures are improving diagnosis rates and patient adherence.

Inflammatory Bowel Disease Treatment Market - IMG1

Innovation in treatment approaches-such as targeted biologics and small molecules-has significantly advanced therapeutic outcomes and reduced treatment-related complications. Government support in the form of public funding and faster regulatory reviews is also encouraging the development and uptake of next-generation therapies. With the patient population growing steadily, demand continues to rise for long-term, effective solutions that improve quality of life and reduce disease flare-ups. Collectively, these factors are shaping a robust and dynamic market environment for IBD therapies over the next decade.

Market Scope
Start Year2024
Forecast Year2025-2034
Start Value$23.9 Billion
Forecast Value$44.5 Billion
CAGR6.5%

In 2024, the Crohn's disease segment held a 56.5% share and is forecasted to grow at a CAGR of 6.3% during 2025-2034. This expansion is largely attributed to an uptick in newly diagnosed cases among younger individuals, particularly across North America and Europe. Crohn's disease tends to require more complex and long-term treatment approaches than ulcerative colitis, given that it can affect any part of the gastrointestinal tract and penetrate deeper layers of tissue. As a result, healthcare providers are increasingly utilizing high-value therapies such as immunosuppressants and biologics. The growing adoption of advanced treatment classes, including Janus kinase inhibitors and anti-integrin agents, has redefined how the disease is managed and significantly contributed to segment growth.

The injectable therapies segment generated the highest revenue in 2024, valued at USD 18.2 billion, and is expected to maintain a CAGR of 6.4% through 2034. This category is led by the widespread use of biologics, particularly monoclonal antibodies, which are generally delivered via injection. These therapies have become the cornerstone for treating moderate to severe IBD by offering precision targeting of inflammation pathways. Agents that modulate immune activity at the molecular level are proving highly effective in maintaining remission and minimizing disease recurrence, especially for patients unresponsive to traditional medications. Long-acting injectables also contribute to higher compliance rates and improved patient satisfaction.

U.S. Inflammatory Bowel Disease Treatment Market was valued at USD 8.8 billion in 2024. Growth in this market is driven by a rising incidence of both Crohn's disease and ulcerative colitis across diverse demographics. Improved diagnostic capabilities, enhanced access to specialists, and expanding use of targeted therapies are all accelerating market development. The availability of innovative drug delivery technologies, such as long-acting subcutaneous injectables and sustained-release formulations, has improved treatment adherence. These advancements are making it easier for patients to manage their conditions and maintain long-term remission, further boosting demand for advanced therapeutics.

Key players operating in the Global Inflammatory Bowel Disease Treatment Market include Pfizer, Biogen, Takeda, Dr Falk, Johnson & Johnson, CELLTRION, AbbVie, Ferring, Merck, UCB, Novartis, Tillotts Pharma, Lilly, and Amgen. These companies continue to influence market direction through strategic investments and innovative drug development. To strengthen their presence in the IBD treatment space, leading pharmaceutical firms are advancing a multi-pronged approach that includes research-driven innovation, regulatory engagement, and collaborative partnerships.

Companies are investing significantly in clinical trials to develop novel biologics and small molecules with improved efficacy and fewer side effects. Expanding product pipelines through licensing deals, mergers, and acquisitions has also become a common strategy. Many are working closely with health authorities to secure accelerated approvals and ensure broad reimbursement access.

Table of Contents

Chapter 1 Methodology and Scope

  • 1.1 Market scope and definitions
  • 1.2 Research design
    • 1.2.1 Research approach
    • 1.2.2 Data collection methods
  • 1.3 Data mining sources
    • 1.3.1 Global
    • 1.3.2 Regional/country
  • 1.4 Base estimates and calculations
    • 1.4.1 Base year calculation
    • 1.4.2 Key trends for market estimation
  • 1.5 Primary research and validation
    • 1.5.1 Primary sources
  • 1.6 Forecast model
  • 1.7 Research assumptions and limitations

Chapter 2 Executive Summary

  • 2.1 Industry 3600 synopsis
  • 2.2 Key market trends
    • 2.2.1 Regional trends
    • 2.2.2 Treatment type trends
    • 2.2.3 Drug class trends
    • 2.2.4 Route of administration trends
    • 2.2.5 Distribution channel trends
  • 2.3 CXO perspectives: Strategic imperatives
    • 2.3.1 Key decision points for industry executives
    • 2.3.2 Critical success factors for market players

Chapter 3 Industry Insights

  • 3.1 Industry ecosystem analysis
  • 3.2 Industry impact forces
    • 3.2.1 Growth drivers
      • 3.2.1.1 Increasing prevalence of IBD
      • 3.2.1.2 Technological advancements
      • 3.2.1.3 Favorable reimbursement policies
      • 3.2.1.4 Growing awareness and early diagnosis of IBD symptoms
    • 3.2.2 Industry pitfalls and challenges
      • 3.2.2.1 Stringent regulatory scenario
      • 3.2.2.2 High cost of treatment
    • 3.2.3 Market opportunities
      • 3.2.3.1 Rising adoption of biologics and targeted therapies
      • 3.2.3.2 Expansion in emerging markets
  • 3.3 Growth potential analysis
  • 3.4 Reimbursement scenario
  • 3.5 Regulatory landscape
  • 3.6 Pipeline analysis
  • 3.7 Investment scenarios outlook
  • 3.8 Treatment switching patterns or sequencing trends
  • 3.9 Epidemiological scenario
  • 3.10 Future market trends/ Key marketed therapies
  • 3.11 Brand analysis
  • 3.12 Porter's analysis
  • 3.13 PESTEL analysis

Chapter 4 Competitive Landscape, 2024

  • 4.1 Introduction
  • 4.2 Company market share analysis
    • 4.2.1 Global
    • 4.2.2 North America
    • 4.2.3 Europe
    • 4.2.4 Asia Pacific
    • 4.2.5 Latin America
    • 4.2.6 MEA
  • 4.3 Competitive analysis of major market players
  • 4.4 Company matrix analysis
  • 4.5 Competitive positioning matrix
  • 4.6 Key developments
    • 4.6.1 Mergers and acquisitions
    • 4.6.2 Partnerships and collaborations
    • 4.6.3 New product launches
    • 4.6.4 Expansion plans

Chapter 5 Market Estimates and Forecast, By Treatment Type, 2021 - 2034 ($ Mn)

  • 5.1 Key trends
  • 5.2 Crohn's disease
  • 5.3 Ulcerative colitis

Chapter 6 Market Estimates and Forecast, By Drug Class, 2021 - 2034 ($ Mn)

  • 6.1 Key trends
  • 6.2 First-line treatment
    • 6.2.1 Aminosalicylates
    • 6.2.2 Corticosteroids
  • 6.3 Second-line treatment
    • 6.3.1 TNF inhibitors
    • 6.3.2 IL inhibitors
    • 6.3.3 JAK inhibitors
    • 6.3.4 Anti-integrin
  • 6.4 Combination therapy
    • 6.4.1 TNF inhibitors + thiopurines
    • 6.4.2 Other combination therapies

Chapter 7 Market Estimates and Forecast, By Route of Administration, 2021 - 2034 ($ Mn)

  • 7.1 Key trends
  • 7.2 Injectable
  • 7.3 Oral

Chapter 8 Market Estimates and Forecast, By Distribution Channel, 2021 - 2034 ($ Mn)

  • 8.1 Key trends
  • 8.2 Brick & mortar
  • 8.3 E-commerce

Chapter 9 Market Estimates and Forecast, By Region, 2021 - 2034 ($ Mn)

  • 9.1 Key trends
  • 9.2 North America
    • 9.2.1 U.S.
    • 9.2.2 Canada
  • 9.3 Europe
    • 9.3.1 Germany
    • 9.3.2 UK
    • 9.3.3 France
    • 9.3.4 Spain
    • 9.3.5 Italy
    • 9.3.6 Netherlands
  • 9.4 Asia Pacific
    • 9.4.1 China
    • 9.4.2 Japan
    • 9.4.3 India
    • 9.4.4 Australia
    • 9.4.5 South Korea
  • 9.5 Latin America
    • 9.5.1 Brazil
    • 9.5.2 Mexico
    • 9.5.3 Argentina
  • 9.6 Middle East and Africa
    • 9.6.1 South Africa
    • 9.6.2 Saudi Arabia
    • 9.6.3 UAE

Chapter 10 Company Profiles

  • 10.1 AbbVie
  • 10.2 Amgen
  • 10.3 Biogen
  • 10.4 CELLTRION
  • 10.5 Dr Falk
  • 10.6 Ferring
  • 10.7 Johnson & Johnson
  • 10.8 Lilly
  • 10.9 Merck
  • 10.10 Novartis
  • 10.11 Pfizer
  • 10.12 Takeda
  • 10.13 Tillotts Pharma
  • 10.14 UCB